"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth. These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you find high-quality companies that can grow their earnings no matter what. Keeping that in mind, here is one industry titan whose competitive advantages creates flywheel effects and two that could be stalling. Two Mega-Cap Stocks to Sell: AbbVie (ABBV) Market Cap: $346.8 billion Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. Why Do We Think Twice About ABBV? Sales were flat over the last two years, indicating it’s failed to expand this cycle Constant currency growth was below our standards over the past two years, suggesting it might need to invest in product improvements to get back on track Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 9.2 percentage points AbbVie is trading at $196 per share, or 15.4x forward P/E. Read our free research report to see why you should think twice about including ABBV in your portfolio, it’s free. Abbott Laboratories (ABT) Market Cap: $230.7 billion With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE:ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Why Are We Hesitant About ABT? Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 1% for the last two years Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion 4.7 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position At $132.40 per share, Abbott Laboratories trades at 24.9x forward P/E. Dive into our free research report to see why there are better opportunities than ABT. One Mega-Cap Stock to Buy: GE Aerospace (GE) Market Cap: $222.8 billion Story Continues One of the original 12 companies on the Dow Jones Industrial Average, General Electric (NYSE:GE) is a multinational conglomerate providing technologies for various sectors including aviation, power, renewable energy, and healthcare. Why Should You Buy GE? Annual revenue growth of 20.1% over the last two years was superb and indicates its market share increased during this cycle Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends, and its recently improved profitability means it has even more resources to invest or distribute Returns on capital are growing as management capitalizes on its market opportunities GE Aerospace’s stock price of $208.84 implies a valuation ratio of 37.3x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free. Stocks We Like Even More Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. View Comments
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...